Ignite Creation Date:
2025-12-25 @ 2:50 AM
Ignite Modification Date:
2026-03-02 @ 6:24 PM
Study NCT ID:
NCT03830333
Status:
COMPLETED
Last Update Posted:
2023-01-17
First Post:
2019-02-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-03-20
Start Date Type:
ACTUAL
Primary Completion Date:
2020-10-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-10-14
Completion Date Type:
ACTUAL
First Submit Date:
2019-02-04
First Submit QC Date:
None
Study First Post Date:
2019-02-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-09-24
Results First Submit QC Date:
None
Results First Post Date:
2021-10-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-13
Last Update Post Date:
2023-01-17
Last Update Post Date Type:
ACTUAL